M&A / Acquisition · Latin America · Announced 19 Nov 2026

Laboratorios Siegfried → Laboratorio Chile

Laboratorio Chile has sold 18 OTC and prescription brands, including the Kitadol paracetamol family, to Grupo Roemmers' Laboratorios Siegfried for US$18.1 million, with a three-year supply contract, as it refocuses on obesity.

Parties: Laboratorios Siegfried (Grupo Roemmers) (Chile) → Laboratorio Chile (Chile)

Value
$18.1m
Territory
Chile
Therapeutic area
Multi-therapy
Assets
Kitadol; Rehsal 60; Rehsal 90; Hiedrix; Cartilar; Cartilar Flex; Solbiot; DryOff; RedOff; Ausentron; Sincris; Hiprex V; Sostac; Tonaril
Announced
19 Nov 2026

Our analysis

Why this matters

Laboratorio Chile has completed the sale of a portfolio of 18 over-the-counter and prescription brands, covering more than 30 presentations, to Laboratorios Siegfried S.A., the Chilean company of Argentina's Grupo Roemmers, for US$18.1 million. The deal was reported on 19 November 2026 by Chilean trade press, with the value first published by El Mercurio. It includes trademarks, sanitary registrations and commercial and digital assets. Named brands include the Kitadol paracetamol family, Rehsal 60 and 90, Hiedrix, Cartilar and Cartilar Flex, Solbiot, DryOff and RedOff, plus prescription products Ausentron, Sincris, Hiprex V, Sostac and Tonaril.

Siegfried has handled commercialisation since 1 October 2026. Laboratorio Chile will keep manufacturing the products and supply them to Siegfried under a three-year contract, and the sanitary registrations, including pharmacovigilance and quality responsibilities, are being transferred at Chile's Institute of Public Health (ISP).

The full analysis is free to read with a work email on this page.

Source: Pharmabiz (citing El Mercurio); Portal Red Salud; Chócale

Latest deals

All Latin America deals → · All m&a / acquisition deals → · Browse all emerging-market pharma deals →